Mucositis Oral
Conditions
Keywords
Children, Oral mucositis, Chemotherapy, Photobiomodulation
Brief summary
Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia. Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies highlighted positive/promising results of PBM with excellent safety and no adverse effects. Nevertheless, a wide variety of application parameters is described in the literature, with no consensus guidelines. Considering the lack of standardized protocol of photobiomodulation in the pediatric population as well as the burden and cost of a daily application, investigators have decided to conduct, for the first time in children of 3 years of age or older, a multicenter, randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with same PBM parameters, combining red and infrared wavelengths, but with different frequencies of laser application (daily versus every other day), in the treatment of chemotherapy-induced OM of WHO grade 2 or higher.
Interventions
RADIATIONLLLT applied every other day
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
RADIATIONLLLT applied daily
Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
Sponsors
University Hospital, Toulouse
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
3 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female children aged ≥ 3 years and \< 18 years. 2. Hospitalization in an oncology or hematology department in the participating centres. 3. Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system) related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell Transplantation (HSCT). 4. Written informed consent of both patient's holders of parental authority, and patient's assent when applicable. 5. Patients affiliated to a French Social Security insurance or equivalent social protection. 6. Absence of any physical or psychological disability that may interfere with the LLLT application.
Exclusion criteria
1. Patients with a solid cancer lesion in the area of low-level laser application. 2. History of cervicofacial radiotherapy. 3. Application of low-level laser therapy for oral mucositis within 2 weeks prior to randomization. 4. Hyperthyroidism defined by TSH \< 0.4 IU/mL at inclusion. 5. Patients susceptible to epilepsy seizure. 6. Patients with pacemaker. 7. Patients refusing to wear retinal goggles during low-level laser 1. Patients with a solid cancer lesion in the area of low-level laser application. 8. Patients protected by law (guardianship and safeguarding of justice). 9. Pregnant female patients as determined by positive serum pregnancy test at screening. 10. Lactating female patients who are actively breast feeding. 11. Participation in another clinical trial involving oral care.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Session evaluation | Throught treatment period up to 1 month | Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health insurance evaluation | 2 months | Costs of inpatient hospital stays from the French health insurance perspective. |
| OM duration evaluation | Throught treatment period up to 1 month | Duration (in days) of chemotherapy-induced OM of WHO grade 2 or higher between the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM at 2 consecutive measurements before the next scheduled PBM session (either every other day application or daily application). |
| OM occurrence | 2 months | Occurrence of chemotherapy-induced OM of WHO grade 3 or 4 (deterioration of the clinical situation). |
| Feed evaluation | 2 months | Occurrence of enteral feeding. |
| Production costs evaluation | 2 months | Production costs from the hospital perspective and efficacy (i.e. number of days after which a child has no longer mucositis related pain as described in the primary endpoint section) to build Incremental Cost-Effectiveness Ratio (ICER) comparing every other day LLLT application versus with daily LLLT application. |
| PBM evaluation | Through treatment period up to 1 month | Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) as evaluated, regardless of patient's age, with the ChIMES scale and use of step 3 analgesics. |
| Pain change evaluation | From baseline to each day of PBM session | Change over time in WHO grade 2 or higher chemotherapy-induced OM related pain, as assessed by pain scales (HEDEN (Hétero Evaluation Douleur Enfant) mucositis scale (5 items ranging from 0 to 2) or VAS (ranging from 0 to 10)depending on patient's age category, and Children's International Mucositis Evaluation Scale (4 items ranging from 0 to 5) whatever patient's age category) |
| Adverse events occurrence | 2 months | Occurrence of adverse events reported according to descriptions and grading scale found in NCI CTCAE version 5.0. |
| thyroid-stimulating hormone (TSH) evolution | From baseline to 2 months | TSH shift from baseline value classified according to the following three categories: \< 0.4 IU/mL, \[0.4 - 10\] IU/mL, \> 10 IU/mL, to value at D14-31 after end of WHO grade 2 or higher chemotherapy-induced OM classified according to the same three categories. |
| Analgesic consumption | 2 months | Duration (in days) of consumption of step 2 and step 3 analgesics during chemotherapy-induced OM of WHO grade 2 or higher. |
Countries
France
Contacts
Primary ContactMarlène PASQUET, MD
Backup ContactGwennaëlle ALPHONSA, CRA
Outcome results
None listed